Beximco Pharmaceuticals, the only Bangladeshi company listed on the London Stock Exchange’s Alternative Investment Market (AIM) since 2005, is facing a major risk of delisting. The company failed to publish its audited financial statements for the 2024–25 fiscal year within the required six months, leading to suspension of its Global Depository Receipt (GDR) trading since January 2, 2026. Under AIM rules, if GDR trading remains suspended for six months, the company may be delisted by early July.

Six institutional investors in London have written to the Bangladesh Securities and Exchange Commission (BSEC) seeking a resolution to avoid delisting. BSEC confirmed it is treating the matter seriously to protect investor interests and Bangladesh’s image. The company’s shares continue normal trading on the Dhaka and Chittagong stock exchanges, but only GDRs are traded in London.

The delay stems from a legal dispute over BSEC’s appointment of independent directors to Beximco Group companies, which halted board meetings needed to approve the financial report. BSEC officials said trading can resume only after court resolution and board approval of the pending audit.